Patients with rheumatoid arthritis experience significantly less psychological stress and physical disability compared with two decades ago, which may be partially due to a reduction in disease activity.
Why rheumatoid arthritis drug trials are using the "non-inferiority" methodology instead of the typical method, according to Lee S. Simon, MD, principal with SDG, LLC.
During their “Great Debate” keynote session of the American College of Rheumatology (ACR) 2013 Annual Meeting in San Diego, CA, two leading rheumatologists took direct aim at each other’s significant clinical trial data to provide rationale for choosing biologics over triple therapy — or vice versa — as the treatment of choice for rheumatoid arthritis (RA).
Although rheumatologists have an array of disease measurement tools to choose from, they generally choose to ignore all of them when they’re assessing rheumatoid arthritis (RA) patients.
As a follow-up to the initial establishment of Simponi (golimumab)’s safety and efficacy in rheumatoid arthritis (RA), researchers presented final 5-year data evaluating the tumor necrosis factor (TNF) blocker’s effects in RA patients taking methotrexate and those naïve to the biologic agent.
Though rheumatoid arthritis (RA) patients have a significantly higher risk of developing cardiovascular disease (CVD) compared to the general population, results from a pair of studies show that the biologic disease modifier Actemra (tocilizumab) may actually improve the cardiovascular (CV) profiles of RA patients.